David Russell, MD
Enriched profileAssistant Clinical Professor in the Department of Psychiatry and Neurology at Yale School of Medicine; Senior Medical Director, Clinical Research, Perceptive New Haven Clinic · Perceptive
David Russell is Assistant Clinical Professor in the Department of Psychiatry and Neurology at Yale School of Medicine; Senior Medical Director, Clinical Research, Perceptive New Haven Clinic at Perceptive. OpenAlex indexes 115 publications with 12,113 citations (h-index 46); ClinicalTrials.gov lists 19 registered studies with this person as an investigator.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
David Russell, M.D., PH.D., is Assistant Clinical Professor in the Department of Psychiatry and Neurology at Yale School of Medicine at Perceptive (formerly Invicro), New Haven, CT. The public record shows 115 publications with 12,113 citations (h-index 46), centered on Parkinson's Disease Mechanisms and Treatments, Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments. It also documents an investigator role on 19 registered clinical trials, industry payments reported by 14 companies, 2 NIH-funded awards (1996–2002).
- Most recent indexed publication: 2025 · Neuropsychopharmacology
- Top research focus: Parkinson's Disease Mechanisms and Treatments
- 19 registered trials on ClinicalTrials.gov
- Open Payments reporting from 14 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 75.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Principal Investigator
Parkinson's Progression Markers Initiative (PPMI) at Institute for Neurodegenerative Disorders (largest worldwide site)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →michaeljfox.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:
- Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein
Sponsor: Invicro
- Plasma P-tau2017 and Quantitative Amyloid PET Imaging
Sponsor: Invicro
Industry payments
Updated 18 Oct 2026
14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Eisai Inc.Program year202524 payments$20,390openpaymentsdata.cms.gov ↗
- Lilly USA, LLCProgram year202514 payments$16,146openpaymentsdata.cms.gov ↗
- UCB SAProgram year20253 payments
NIH funding
Updated 18 Oct 2026
2 NIH research awards on record, funded 1996–2002 per NIH RePORTER. The latest:
- Modulation of epigenetic programming of tissue resident macrophage lineages to impact HIV-1 infection, maintenance, and persistence.
Cornell University
FY2026$482,843R01AI176575 - Minimizing in vivo Drug Tolerance induction in tuberculosis.
Rutgers Biomedical and Health Sciences
FY2025$900,091U19AI162598 - Modulation of epigenetic programming of tissue resident macrophage lineages to impact HIV-1 infection, maintenance, and persistence.
Cornell University
FY2025$482,843R01AI176575
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study.
Neuropsychopharmacology
Article2025 - The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases.
Nature communications
Article2023 - Binding characteristics of [(18)F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET.
Journal of cerebral blood flow and metabolism
Article2021
Most-cited works
by citation count (OpenAlex)- 01The Parkinson Progression Marker Initiative (PPMI)Article1,901 citations2011
- 02Brain-Derived Neurotrophic Factor Produces Antidepressant Effects in Behavioral Models of DepressionArticle1,653 citations2002
- 03
- 04Regulation of affect by the lateral septum: implications for neuropsychiatryArticle512 citations2004
- 05Voluntary exercise produces antidepressant and anxiolytic behavioral effects in miceArticle463 citations2008
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
medicine.yale.edu/profile/david-russell
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Other
michaeljfox.org/researcher/david-russell-md-phd
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →michaeljfox.org ↗ - Other
perceptive.com
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →perceptive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →perceptive.com ↗
Editorial & leadership roles
journal and society appointments- Member
Parkinson Study Group
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →michaeljfox.org ↗ - Member
Huntington Study Groups
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →michaeljfox.org ↗ - Member
Movement Disorders Society
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →michaeljfox.org ↗
Secondary affiliations
appointments beyond the home institution- Yale School of Medicine
Department of Psychiatry and Neurology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Institute for Neurodegenerative Disorders
Director of Clinical Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →michaeljfox.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Bruce Miller, MD
University of California, San Francisco (UCSF)
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
Steven Dekosky, MD
University of Florida Health